ClinicalTrials.gg

Program

Sinovac PCV24 formulation 1

Also written as “Sinovac PCV24 formulation 2” and “Sinovac PCV24”.

Its studies are mostly in Pneumococcal Infections, led by Sinovac Biotech.

Furthest: phase 2, since Nov 24, 20254 company-led studies, 2 open or running

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Sinovac Biotech42 open or runningphase 2since Nov 24, 2025Jun 19, 2024none ahead

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Jun 19, 2024First study: phase 1 study in Pneumococcal InfectionsFirst studyNCT06474377 · 170 enrolled · China
  2. Aug 8, 2024Phase 1 study in Pneumococcal InfectionsNCT06550830 · 119 enrolled · China
  3. Jan 23, 2025Phase 1 study in Pneumococcal InfectionsNCT06800261 · 180 planned · China
  4. Nov 24, 2025Phase 2 study in Pneumococcal InfectionsPhase 2 reachedNCT07300644 · 420 planned · China

TargetBeta

Not stated by its company or a source we have read. Most early programs say nothing of it.

Studies

All 4 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT07300644Pneumococcal Infections · China2RecruitingSep 2026420
NCT06800261Pneumococcal Infections · China1RecruitingJun 2026180
NCT06550830Pneumococcal Infections · China1CompletedJun 25, 2025119
NCT06474377Pneumococcal Infections · China1CompletedAug 26, 2024170

How it is read

Names in the registry

  • “Sinovac PCV24 formulation 1”, 2 entries
  • “Sinovac PCV24 formulation 2”, 2 entries
  • “Sinovac PCV24”, 2 entries

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.